Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-2403 BI-MAPS ivonescimab salvage therapy in relapsing pleural mesothelioma
2024-519052-82-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pleural mesothelioma, sponsored by IFCT. Primary endpoint: Disease control rate at 12 weeks. Planned start Jun 2025; status: authorised.
02
Drugs
ivonescimab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-519052-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519052-82-00.